Leading the World in Science
Our vision is to make life-changing medicines using world-leading science and our objective is to become one of Japan’s global biopharmaceutical champions.
Currently, the Group's core businesses are developed by bringing together the world-leading drug discovery platform at our R&D Center in Cambridge, UK, and our strong late-stage clinical and commercialization platform in Japan and APAC. In addition to organic growth through these core businesses, we will continue to enhance our corporate value through unprecedented means compared with other pharmaceutical companies, just as we have achieved strategic and transformative growth through the acquisitions of Arakis in 2005, Heptares in 2015, and Idorsia (Japan and Korea) in 2023.
I would like to thank our shareholders and investors who supported our growth, and we remain committed to sharing with our shareholders and investors the fruits of greater success that we will reap as we make contributions to many patients around the world.
I would like to reiterate my sincere thanks to shareholders and investors for their understanding, and I look forward to your continued support.